VKTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VKTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viking Therapeutics has the Growth Rank of 0.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
Thank you for viewing the detailed overview of Viking Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Lian | director, officer: President & CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Greg Zante | officer: Chief Financial Officer | C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804 |
Marianna Mancini | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130 |
Lawson Macartney | director | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
J Matthew Singleton | director | 286 STANWICH ROAD, GREENWICH CT 06830 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Matthew W Foehr | director | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
Ligand Pharmaceuticals Inc | 10 percent owner | 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Hiroko Masamune | officer: Chief Development Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Michael Morneau | officer: Chief Financial Officer | C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Stephen W Webster | director | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Rochelle Hanley | officer: Chief Medical Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
Michael Dinerman | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
From GuruFocus
By GuruFocus News • 11-09-2024
By GuruFocus News • 02-06-2025
By Faizan Farooque • 02-06-2025
By PRNewswire • 12-04-2024
By PRNewswire • 01-06-2025
By PRNewswire • 03-04-2025
By GuruFocus News • 01-29-2025
By PRNewswire • 01-08-2025
By GuruFocus News • 01-08-2025
By GuruFocus News • 03-12-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.